Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey.

Harrison CN, Koschmieder S, Foltz L, Guglielmelli P, Flindt T, Koehler M, Mathias J, Komatsu N, Boothroyd RN, Spierer A, Perez Ronco J, Taylor-Stokes G, Waller J, Mesa RA.

Ann Hematol. 2017 Oct;96(10):1653-1665. doi: 10.1007/s00277-017-3082-y. Epub 2017 Aug 5.

2.

Megakaryocytic morphology in Janus kinase 2 V617F positive myeloproliferative neoplasm.

Ghai S, Rai S.

South Asian J Cancer. 2017 Apr-Jun;6(2):75-78. doi: 10.4103/2278-330X.208854.

3.

Myeloproliferative Disease: An Unusual Cause of Raynaud's Phenomenon and Digital Ischaemia.

Beynon C, Huws G, Lawson T.

Case Rep Med. 2016;2016:9675171. Epub 2016 Nov 8.

4.

Risk of second primary malignancies in a population-based study of adult patients with essential thrombocythemia.

Shrestha R, Giri S, Pathak R, Bhatt VR.

World J Clin Oncol. 2016 Aug 10;7(4):324-30. doi: 10.5306/wjco.v7.i4.324.

5.

Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study.

Naqvi K, Daver N, Pemmaraju N, Bose P, Garcia-Manero G, Cortes J, Kantarjian HM, Verstovsek S.

Leuk Lymphoma. 2017 Apr;58(4):866-871. doi: 10.1080/10428194.2016.1217528. Epub 2016 Aug 5.

6.

Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12.

Srour SA, Devesa SS, Morton LM, Check DP, Curtis RE, Linet MS, Dores GM.

Br J Haematol. 2016 Aug;174(3):382-96. doi: 10.1111/bjh.14061. Epub 2016 Apr 7. Erratum in: Br J Haematol. 2017 Apr;177(2):331.

7.

Multimodality imaging of osseous involvement In haematological malignancies.

Keraliya AR, Krajewski KM, Jagannathan JP, Shinagare AB, Braschi-Amirfarzan M, Tirumani SH, Ramaiya NH.

Br J Radiol. 2016;89(1059):20150980. doi: 10.1259/bjr.20150980. Epub 2016 Jan 19. Review.

8.

Myeloproliferative Neoplasms in Children.

Hofmann I.

J Hematop. 2015 Sep;8(3):143-157. Epub 2015 Aug 2.

9.

A comprehensive review of pacritinib in myelofibrosis.

Verstovsek S, Komrokji RS.

Future Oncol. 2015;11(20):2819-30. doi: 10.2217/fon.15.200. Epub 2015 Sep 14. Review.

10.

Management of thrombocythemia.

Gowin K, Mesa R.

F1000Res. 2014 Sep 29;3:227. doi: 10.12688/f1000research.5361.1. eCollection 2014.

11.

Comorbidities predict worse prognosis in patients with primary myelofibrosis.

Newberry KJ, Naqvi K, Nguyen KT, Cardenas-Turanzas M, Florencia Tanaka M, Pierce S, Verstovsek S.

Cancer. 2014 Oct 1;120(19):2996-3002. doi: 10.1002/cncr.28857. Epub 2014 Jun 10.

12.

Efficacy of ruxolitinib for myelofibrosis.

Santos FP, Verstovsek S.

Expert Opin Pharmacother. 2014 Jul;15(10):1465-73. doi: 10.1517/14656566.2014.923404. Epub 2014 May 24. Review.

13.

Survival patterns in United States (US) medicare enrollees with non-CML myeloproliferative neoplasms (MPN).

Price GL, Davis KL, Karve S, Pohl G, Walgren RA.

PLoS One. 2014 Mar 11;9(3):e90299. doi: 10.1371/journal.pone.0090299. eCollection 2014.

14.

Symptom burden and splenomegaly in patients with myelofibrosis in the United States: a retrospective medical record review.

Mitra D, Kaye JA, Piecoro LT, Brown J, Reith K, Mughal TI, Sarlis NJ.

Cancer Med. 2013 Dec;2(6):889-98. doi: 10.1002/cam4.136. Epub 2013 Oct 5.

15.

Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor.

Verstovsek S, Tam CS, Wadleigh M, Sokol L, Smith CC, Bui LA, Song C, Clary DO, Olszynski P, Cortes J, Kantarjian H, Shah NP.

Leuk Res. 2014 Mar;38(3):316-22. doi: 10.1016/j.leukres.2013.12.006. Epub 2013 Dec 11.

16.

Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.

Choong ML, Pecquet C, Pendharkar V, Diaconu CC, Yong JW, Tai SJ, Wang SF, Defour JP, Sangthongpitag K, Villeval JL, Vainchenker W, Constantinescu SN, Lee MA.

J Cell Mol Med. 2013 Nov;17(11):1397-409. doi: 10.1111/jcmm.12156. Epub 2013 Nov 19.

17.

Expanding the SHOC2 mutation associated phenotype of Noonan syndrome with loose anagen hair: structural brain anomalies and myelofibrosis.

Gripp KW, Zand DJ, Demmer L, Anderson CE, Dobyns WB, Zackai EH, Denenberg E, Jenny K, Stabley DL, Sol-Church K.

Am J Med Genet A. 2013 Oct;161A(10):2420-30. doi: 10.1002/ajmg.a.36098. Epub 2013 Aug 5.

18.

When the Brakes are Lost: LNK Dysfunction in Mice, Men, and Myeloproliferative Neoplasms.

Oh ST.

Ther Adv Hematol. 2011 Feb;2(1):11-9. doi: 10.1177/2040620710393391.

19.

Emerging therapeutic options for myelofibrosis: a Canadian perspective.

Gupta V, Foltz L, Sirhan S, Busque L, Turner AR.

Am J Blood Res. 2012;2(3):170-86. Epub 2012 Sep 23.

20.

Acute Myeloid Leukemia Evolving from JAK 2-Positive Primary Myelofibrosis and Concomitant CD5-Negative Mantle Cell Lymphoma: A Case Report and Review of the Literature.

Treaba DO, Khedr S, Mangray S, Jackson C, Castillo JJ, Winer ES.

Case Rep Hematol. 2012;2012:875039. doi: 10.1155/2012/875039. Epub 2012 Aug 2.

Supplemental Content

Support Center